和康生物科技股份有限公司
MAXIGEN BIOTECH INC.

Q4 2024 法 人 說 明 會

IR Contact/Spokesperson
Grace Fu
grace.fu@tci-bio.com

SAFE HARBOR NOTICE

TCI's statements of its current expectations are forwardlooking statements subject to significant risks and uncertainties and actual results may differ materially from those contained in the forward-looking statements.
Except as required by law, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

膠原蛋白及玻尿酸生技醫療公司

股票代號 1783
員工數 150 人
2021 年營收 NTD 5.12 億元

1998
公司成立

2006
生醫材料
獲美國FDA認證

2013
正式掛牌上市

2017
生醫材料
獲印尼上市許可證

2018
生醫材料獲
俄羅斯、馬來西亞、台灣
上市許可證

2019
生醫材料獲
歐盟CE許可證

2021
大江生醫成為最大股東
林詠翔先生出任董事長

台塑生醫
以私募方式入股

獲馬來西亞3項產品認證

2022
取得馬來西亞、印尼、
菲律賓、印度上市許可證

芙媄登於中國東方整形美容藝術大會
重磅上市

2023
已獲准牙科基材
於阿拉伯聯合大公國上市

皮膚填補劑馬來西亞技術審查獲准

預計取得越南、澳洲、
埃及、約旦、吉爾吉斯
上市許可證

2023
據統計2023年共取證之
產品品項有共計22個品
項，公司至今共累計81
項產品具有許可證資質

2024
關節注射劑取得沙烏地阿拉伯、澳洲與秘魯許可；膠原敷材(HAD, HAS)取得越南、泰國許可；新一代鼻腔敷料(NAS)可進入美國/台灣市場

截至H1共獲得11項產品之各國許可，整體至今累計產品品項共92項有許可證。

Developing Future

2024 Q3 產品行銷活動 – 台灣地區

10/19-20 Annual Meeting Taiwan Academy of Periodontology




8/25 To Be A Real Bone Builder

9/8 United Dental Exhibition




8/17-18 Asia Pacific Association of Implant Dentistry

2024 Q3
產品行銷
研討會

8/24 Formaderm®Dermal Filler Workshop Online Seminar

7/29-30 CN Dental Workshop

7/19 Membrane Perfectly Aid Online seminar

10/6 Upper Facial Micro-Plastic Surgery Course

Sales Breakdown By Product



Q3 2024



Q2 2024



Q3 2023

Sales Breakdown By Region



Q3 2024



Q2 2024



Q3 2023

Q3 2024

財務總覽

Financial Review

Q3 2024 損益表

Consolidated Financial Report

(in TWD $ million)	Q3 2024		Q2 2024		QoQ	Q3 2023		YoY
	Amount	%	Amount	%	%	Amount	%	%
Operating Revenue	174	100%	174	100%	0%	159	100%	9%
Gross Margin	128	74%	116	67%	10%	108	68%	19%
Operating Expenses	-78	-45%	-76	-44%	3%	-82	-52%	-4%
- Selling	-20	-12%	-28	-16%	-28%	-37	-23%	-46%
- G&A	-21	-12%	-20	-12%	5%	-20	-13%	6%
- R&D	-31	-18%	-25	-14%	26%	-25	-16%	25%
- Expected Credit Losses	-6	-3%	-3	-2%	94%	0	0%	-
Operating Profit	50	29%	40	23%	24%	26	16%	92%
Non-Operating Income	20	11%	7	4%	186%	29	18%	-31%
Income Tax	-20	-12%	12	7%	-	-13	-8%	57%
Net Profit After Tax	50	28%	60	34%	-17%	42	26%	18%
Net Profit Attributable to Shareholders of the Parent	50	28%	60	34%	-17%	42	26%	18%
Basic EPS	0.56		0.66		-15%	0.47		19%

Q3 2024 資產負債表 Selected Items from Balance Sheet

(in TWD $ million)	Q3 2024 Amount	%	Q2 2024 Amount	%	Q3 2023 Amount	%
Cash & Cash Equivalent	545	36%	522	33%	421	27%
Account Receivables	113	7%	125	8%	111	7%
Inventories	75	5%	70	4%	97	6%
Net PP&E	800	52%	850	54%	914	59%
Total Assets	1,533	100%	1,567	100%	1,543	100%
Short-Term Debt	-	0%	-	0%	-	0%
Current Liabilities	198	13%	237	15%	174	11%
Total Liabilities	198	13%	237	15%	174	11%
Total Shareholders' Equity	1,335	87%	1,331	85%	1,369	89%

Q3 2024 現金流量表

Cash Flow Statement

(in TWD $ million)	Q3 2024 Amount	Q2 2024 Amount	Q3 2023 Amount
Beginning Balance	431	431	791
Cash from Ops.	215	99	114
Cash from Investing	-20	-13	-485
Cash from Financing	-80	5	0
Foreign Exchange Rate Adj.	-2	-1	0
Ending Balance	544	521	420
Free Cash Flow*	203	86	100


Q
A